Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
about
STX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3(1)/SV40 T/t-antigen transgenic miceThe related transcriptional enhancer factor-1 isoform, TEAD4(216), can repress vascular endothelial growth factor expression in mammalian cellsPEI-g-PEG-RGD/small interference RNA polyplex-mediated silencing of vascular endothelial growth factor receptor and its potential as an anti-angiogenic tumor therapeutic strategyMacrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies.The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma.Breast cancer stem cells, cytokine networks, and the tumor microenvironment.Functional VEGF and VEGF receptors are expressed in human medulloblastomasThe promise of genetically engineered mice for cancer prevention studies.One cell, multiple roles: contribution of mesenchymal stem cells to tumor development in tumor microenvironment.Genetic and epigenetic alterations in breast cancer: what are the perspectives for clinical practice?Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis.Anti-tumor effect of estrogen-related receptor alpha knockdown on uterine endometrial cancer.Growth factors as active participants in carcinogenesis: a perspective.Kinase inhibitors as potential agents in the treatment of multiple myeloma.DNA methylome profiling beyond promoters - taking an epigenetic snapshot of the breast tumor microenvironment.The Chick Embryo Chorioallantoic Membrane as an In Vivo Assay to Study Antiangiogenesis.Human head and neck squamous cell carcinoma cells are both targets and effectors for the angiogenic cytokine, VEGF.Increased expression of VEGF121/VEGF165-189 ratio results in a significant enhancement of human prostate tumor angiogenesis.Hydrodynamics-based gene delivery of naked DNA encoding fetal liver kinase-1 gene effectively suppresses the growth of pre-existing tumors.Phosphorylated KDR expression in endometrial cancer cells relates to HIF1α/VEGF pathway and unfavourable prognosis
P2860
Q28536340-C58ECD0B-B1BE-4582-BC48-9B62885DDBB2Q28728051-C86D6228-F6C8-4FD5-AF97-767329E3F9E8Q34805909-90C88FCF-AE38-41DB-B463-7286D9287E47Q35221807-4BE2E6B1-8EE4-415C-B3DF-602B9D22C3B6Q35540030-B13ECB82-8244-4411-83C2-35A19F8269A5Q35571904-A029B00B-0055-436E-9659-9BF590285034Q36013314-8A67BD40-A5B9-4D2B-A4D7-E77BD9437554Q36058466-9312B8B2-B404-4C86-BA4F-EBA1DA0CEBBBQ36958177-ED6386AA-E52E-499D-AA1B-8F87B02ECCEBQ37025333-65AB3FA3-21CA-4DC1-B3F1-FD4DB4330DBAQ37243488-AB3F027A-09D8-4390-8CD6-3996C3FC54B8Q37376218-6704A8F3-BE94-45E2-A996-E16DED662846Q37676697-0ECD32AA-638F-4F3C-BC42-15919A300A39Q37697253-B927B185-CB4F-40B5-A897-BF67D69FA62DQ38261602-CF2C629E-2957-431A-AD31-6C0A6C5E7E46Q38974193-2E89EFF5-F21D-42E2-A474-944304E12A15Q39938141-C3C41BE1-9264-4D90-9BE4-C0C2E03B6693Q40174585-050F4D92-FF05-4462-A7A6-9E575D4BA6A4Q40269728-8D12B8BD-1D4D-428E-BC2F-005F466F8792Q58211896-2308772A-CFAF-490A-850B-49FC6FEACE98
P2860
Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Inhibition of VEGF receptors s ...... non-antiangiogenic mechanisms.
@en
type
label
Inhibition of VEGF receptors s ...... non-antiangiogenic mechanisms.
@en
prefLabel
Inhibition of VEGF receptors s ...... non-antiangiogenic mechanisms.
@en
P2093
P2860
P356
P1433
P1476
Inhibition of VEGF receptors s ...... non-antiangiogenic mechanisms.
@en
P2093
Alfonso Calvo
Deborah Philp
Hynda K Kleinman
Jeffrey E Green
Jeffrey Stafford
Jung-Im Huh
Mui Cheung
Rakesh Kumar
P2860
P2888
P304
P356
10.1038/SJ.ONC.1208221
P407
P577
2005-01-01T00:00:00Z
P5875
P6179
1003550506